Search bioRxiv⌕ Search

Biology subjects

Morris, G. M.

Publications and source records attributed to Morris, G. M..

4 recordsLinked to original sources

Protein-Ligand Interaction Graphs: Learning from Ligand-Shaped 3D Interaction Graphs to Improve Binding Affinity Prediction

Graph Neural Networks (GNNs) have recently gained in popularity, challenging molecular fingerprints or SMILES-based representations as the predominant way to represent molecules for binding affinity prediction. Although simple ligand-based graphs alone are already useful for affinity prediction, better performance on multi-target datasets has been achieved with models that incorporate 3D structural information. Most recent advances utilize complex GNN architectures to capture 3D protein-ligand information by incorporating ligand-interacting protein atoms as additional nodes in the graphs; or by building a second protein-based graph in parallel. This expands the graph considerably while obfuscating the shape of the underlying ligand, diminishing the advantage that GNNs have when encoding molecular structures. There is therefore a need for a simple and elegant molecular graph representation that retains the topology of the ligand while simultaneously encoding 3D protein-ligand interactions. We present Protein-Ligand Interaction Graphs (PLIGs): a simple way of representing atom-atom contacts of 3D protein-ligand complexes as node features for GNNs. PLIGs featurize an atom node in the molecular graph by describing each atoms properties as well as all atom-atom contacts made with protein atoms within a distance threshold. The edges of the graph are therefore identical to ligand-based graphs, but the nodes encode the 3D protein-ligand contacts. Since PLIGs are applicable to any GNN architecture, we have benchmarked their performance with six different GNN architectures, and compared them to conventional ligand-based graphs and fingerprint-based multi-layer perceptron (MLP) models using the CASF-2016 benchmark set where we found PLIG-based Graph Attention Networks (GATNet) to be the best performing model ({rho}=0.84, RMSE=1.22 pK). In summary, we created a novel graph-based representation that incorporates 3D structural information into the node features of ligand-shaped molecular graphs. The PLIG representation is simple, elegant, flexible and easily customizable, opening up many possibilities of incorporating other 2D and 3D properties into the graph. AccessThe code and implementation for PLIGs and all models can be found at github.com/MarcMoesser/Protein-Ligand-Interaction-Graphs.

bioinformatics↗

Understanding the Genetics of Viral Drug Resistance by Integrating Clinical Data and Mining of the Scientific Literature

Drug resistance caused by mutations is a public health threat for existing and emerging viral diseases. A wealth of evidence about these mutations and their clinically-associated phenotypes is scattered across the literature, but a comprehensive perspective is usually lacking. This work aimed to produce a clinically-relevant view for the case of Hepatitis B virus (HBV) mutations by combining a chronic HBV clinical study with a compendium of genetic mutations systematically gathered from the scientific literature. We enriched clinical mutation data by systematically mining 2,472,725 scientific articles from PubMed Central in order to gather information about the HBV mutational landscape. By performing this analysis, we were able to identify mutational hotspots for each HBV genotype (A-E) and gene (C, X, P, S), as well as the location of disulfide bonds associated with these mutations. Through a modelling study, we also identified a mutational position common in both the clinical data and the literature that is located at the binding pocket for a known anti-HBV drug, namely entecavir. The results of this novel approach shows the potential of integrated analyses to assist in the development of new drugs for viral diseases that are more robust to resistance. Such analyses should be of particular interest due to the increasing importance of viral resistance in established and emerging viruses, such as for newly-developed drugs against SARS-CoV-2.

bioinformatics↗

Discovery of SARS-CoV-2 Mpro Peptide Inhibitors from Modelling Substrate and Ligand Binding

The main protease (Mpro) of SARS-CoV-2 is central to its viral lifecycle and is a promising drug target, but little is known concerning structural aspects of how it binds to its 11 natural cleavage sites. We used biophysical and crystallographic data and an array of classical molecular mechanics and quantum mechanical techniques, including automated docking, molecular dynamics (MD) simulations, linear-scaling DFT, QM/MM, and interactive MD in virtual reality, to investigate the molecular features underlying recognition of the natural Mpro substrates. Analyses of the subsite interactions of modelled 11-residue cleavage site peptides, ligands from high-throughput crystallography, and designed covalently binding inhibitors were performed. Modelling studies reveal remarkable conservation of hydrogen bonding patterns of the natural Mpro substrates, particularly on the N-terminal side of the scissile bond. They highlight the critical role of interactions beyond the immediate active site in recognition and catalysis, in particular at the P2/S2 sites. The binding modes of the natural substrates, together with extensive interaction analyses of inhibitor and fragment binding to Mpro, reveal new opportunities for inhibition. Building on our initial Mpro-substrate models, computational mutagenesis scanning was employed to design peptides with improved affinity and which inhibit Mpro competitively. The combined results provide new insight useful for the development of Mpro inhibitors.

bioinformatics↗

Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification

The SARS-CoV-2 coronavirus (CoV) causes COVID-19, a current global pandemic. SARS-CoV-2 belongs to an order of Nidovirales with very large RNA genomes. It is proposed that the fidelity of CoV genome replication is aided by an RNA nuclease complex, formed of non-structural proteins 14 and 10 (nsp14-nsp10), an attractive target for antiviral inhibition. Here, we confirm that the SARS-CoV-2 nsp14-nsp10 complex is an RNase. Detailed functional characterisation reveals nsp14-nsp10 is a highly versatile nuclease capable of digesting a wide variety of RNA structures, including those with a blocked 3-terminus. We propose that the role of nsp14-nsp10 in maintaining replication fidelity goes beyond classical proofreading and purges the nascent replicating RNA strand of a range of potentially replication terminating aberrations. Using the developed assays, we identify a series of drug and drug-like molecules that potently inhibit nsp14-nsp10, including the known Sars-Cov-2 major protease (Mpro) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the potential for bifunctional inhibitors in the treatment of COVID-19.

biochemistry↗